ECCO 2021

Role of JAKi in IBD: What’s new in 2021?

IL23 inhibiton: Efficacy & Safety Updates

Comparing the different modes of action in IBD: Selection & Positioning

Novel agents: Do we need new drugs or just combinations?

Imaging: routine care vs. clinical trial setting? The predictive value of ultrasonography

Artificial Intelligence in IBD ... Even today a part of clinical care!

What are the therapeutic goals in IBD? Clinical goals vs. patient oriented goals (disease clearance, endoscopic healing, transmural healing, normal QoL, ...)

Therapeutic algorithms: How to define? Transfering trial data into routine care? Hit hard, hit early!

AI: The new frontier in endoscopy interpretation

AI - Has artificial intelligence reached IBD

AI is coming!

Classification through AI is coming!

Intelligenza artificiale: la nuova frontiera in endoscopia per la quantificazione dell'infiammazione intestinale

Künstliche Intelligenz hilfreich bei Auswertung endoskopischer Befunde

AI está llegando!

L'intelligence artificielle arrive dans la RCH !

New Therapeutic Strategies: STARDUST treat-to-target trial with Ustekinumab in Crohn's Disease

SEAVUE - Head-to-head comparison: Applicable for daily practice?

SEAVUE: Early intervention leads to great remission; STARDUST: Treat to Target - better for patients with high endoscopic disease

SAEVUE: The 1st biologic head-to-head trial in Crohn's Disease

SEAVUE: no difference in remission between ustekinumab and adalimumab. Early treatment is most important!

Which treatment for acute/severe UC after steroid failure

The SEAVUE Trial - will it help us to guide and position our treatment in Crohn's disease?

SEAVUE: From efficacy to pharmacoeconomic perspectives

More JAK inhibitors - same questions!

Need for early resection in Crohn's disease is not associated with poor prognosis - long-term follow-up data from Denmark

Welche Therapiestrategie für welches Therapieziel?

Adalimumab vs Ustekinumab: dai risultati di confronto diretto alla partica clinica?

SEAVUE: Early intervention leads to great remission; STARDUST: Treat to Target - better for patients with high endoscopic disease

Enfin un seuil avec l'UCEIS !

Badanie SEAVUE - czy pomoże nam pozycjonować leki biologiczne i poprawić wyniki leczenia choroby Leśniowskiego-Crohna?

Leczenie chirurgiczne na bardzo wczesnym etapie choroby Leśniowskiego-Crohna nie prognozuje niekorzystnego przebiegu choroby w obserwacji długoterminowej

Predictive value of Milan Ultrasound in UC

PREdiCCt: Predictive factors associated with fatigue in IBD

Hot topic: Intestinational ultrasound for disease monitoring in Crohn's Disease

Towards UCEIS cutoff in UC

Liquid biopsy as a novel non-invasive biomarker in IBD

Symsptoms and signs assocation - the value of histology

VARSITY: Epithelial neutrophils are very important actors in Ulcerative Colitis

Liquid biopsy opens exciting window for biomarker monitoring

Prädiktiver Wert des Darmultraschalls bei UC

PREdiCCt: Fatigue assoziierte prädiktive Faktoren

Hot topic: Tarmultralyd til monitorering af Crohn's sygdom

Quel traitement d'entretien en cas de colite aiguë grave cortico-sensible ?

New Therapeutic Treatments in IBD: JAKi

IL-12/23 Blockade: Mechanism of action

New drugs with signifiicant efficacy: ritlecitinib, brepocitinib, upadacitinib

Upadacitinib: Impressive induction data in Ulcerative Colitis

Results form phase 3 induction studies with Upadacitinib in Ulcerative Colitis: U-ACCOMPLISH/U-ACHIEVE

Upadacitinib significantly effective in UC (U-ACCOMPLISH)

IL-23 inhibition with risankizumab effective for biologically treatment naive and preexposed patients (ADVANCE and MOTIVATE)

SELECTION updates: no apparent safety concerns for filgotinib

ADVANCE and MOTIVATE: Risankizumab with fast induction kinetics

VIBRATO: Ritlecitinib and brepocitinib both effective. Ritlecitinib with more benefit from new mode of action.

Neue Daten zu JAK-Inhibitoren

Neue Aspekte zu IL-12 und IL-23-Antikörpern

New drugs with signifiicant efficacy: ritlecitinib, brepocitinib, upadacitinib

Resultaten van de fase 3 inductie studies met upadacitinib in colitis ulcerosa: U-ACCOMPLISH/U-ACHIEVE

Ritlecitinib und Brepocitinib: Neue Targets der JAK-Inhibition bei CU

Anti-IL-23 Antikörper könnten potentielle Game-changer bei MC sein

Providing CLARITY on COVID-19 in IBD

5-ASA - back from the other side? New COVID-19 safety data from the SECURE-IBD cohort

Immune response to anti-SARS-CoV-2 vaccinations in different treatment subgroups of IBD patients. What has been clarified by the CLARITY IBD study so far?

5-ASA - powrót z zaświatów? Nowe dane z badania SECURE-IBD, dotyczące bezpieczeństwa terapii 5-ASA w dobie pandemii COVID-19.

Odpowiedź immunologiczna na szczepienia przeciw SARS-CoV-2 u chorych z IBD. Czy leczenie ma wpływ i co to może oznaczać dla naszych pacjentów?

Wide spectrum of treatments for IBD

Espectro de tratamientos amplio para IBD?

Appendectomy for Ulcerative Colitis

My perspective on ECCO2021

Increasing prevalence of IBD in Brazil

Update ECCO-Guideline on Vaccination and Vaccination Strategy

CRAFT UC: Diet more effective than FMT? We need more data

Fecal transplantation or diet for Ulcerative Colitis?

Stigende forekomst af IBD i Brasilien

Appendektomi ved patienter med colitis ulcerosa

Konditionierte Diät ist der FMT bei CU überlegen

Neue ECCO-Leitlinie zu Infektionen und Impstrategie

El ECCO 2021 desde mi punto de vista

Stoelgangstransplantatie of dieet voor colitis ulcera?